PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers

Jorge D Oldan; Jennifer A Schroeder; Jean Hoffman-Censits; W Kimryn Rathmell; Matthew I Milowsky; Lilja B Solnes; Sridhar Nimmagadda; Michael A Gorin; Amir H Khandani; Steven P Rowe

doi:10.1016/j.cpet.2023.12.006

PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers

PET Clin. 2024 Apr;19(2):197-206. doi: 10.1016/j.cpet.2023.12.006. Epub 2024 Jan 9.

Affiliations

¹ Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, NC, USA.
² Department of Medical Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
⁵ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁶ Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁷ Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: Steven_Rowe@med.unc.edu.

PMID: 38199916
DOI: 10.1016/j.cpet.2023.12.006

Abstract

Renal cell carcinoma (RCC) and urothelial carcinoma (UC) are two of the most common genitourinary malignancies. 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG) can play an important role in the evaluation of patients with RCC and UC. In addition to the clinical utility of 18F-FDG PET to evaluate for metastatic RCC or UC, the shift in molecular imaging to focus on specific ligand-receptor interactions should provide novel diagnostic and therapeutic opportunities in genitourinary malignancies. In combination with the rise of artificial intelligence, our ability to derive imaging biomarkers that are associated with treatment selection, response assessment, and overall patient prognostication will only improve.

Keywords: Carbonic anhydrase IX; Renal cell carcinoma; Urothelial carcinoma.

Publication types

Review

MeSH terms

Artificial Intelligence
Carcinoma, Renal Cell* / diagnostic imaging
Carcinoma, Renal Cell* / secondary
Carcinoma, Transitional Cell* / diagnostic imaging
Fluorodeoxyglucose F18
Humans
Kidney
Kidney Neoplasms* / diagnostic imaging
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography / methods
Tomography, X-Ray Computed
Urinary Bladder Neoplasms* / therapy
Urologic Neoplasms* / diagnostic imaging

Substances

Fluorodeoxyglucose F18